

LifeSci Biotechnology Clinical Trials Index

2/20/2024

Effective at the market close on Thursday, February 22, 2024, **RYZB** will be removed from the **LifeSci Biotechnology Clinical Trials Index** and its value will be redistributed to the remaining index components based on their weights.

- On December 26, 2023, RayzeBio, Inc. announced that it would be acquired by Bristol Myers for \$62.50/share in cash.